➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Moodys
Medtronic
Harvard Business School
Mallinckrodt

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,761,471

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,761,471
Title: Bone morphogenetic protein composition
Abstract:BMP compositions including the human factor and bovine factor thereof, the process of isolating BMP compositions and factors, and the use of such factors and compositions to induce bone formation in animals.
Inventor(s): Urist; Marshall R. (Pacific Palisades, CA)
Assignee: The Regents of the University of California (Berkley, CA)
Application Number:06/899,020
Patent Claims:1. Substantially pure bone morphogenetic protein composition comprising BMP factor and at least one BMP associated protein selected from a group consisting of BMP associated proteins having molecular weights in the range of between about 14 dKa and about 34 kDa, said BMP factor being capable of inducing bone formation independent of the presence of said BMP associated proteins, and said BMP associated proteins being incapable of inducing bone formation independent of the presence of said BMP factor.

2. The bone morphogenetic protein composition of claim 1, wherein the BMP factor is human BMP factor having a molecular weight of 17.5.+-.0.5 dKa, and the BMP associated proteins are human BMP associated proteins having molecular weights of about 14-, 22-, 24- and 34-kDa.

3. The bone morphogenetic protein composition of claim 1, wherein the BMP factor is bovine BMP factor having a molecular weight of 18.5.+-.0.5 kDa, and the BMP associated proteins are bovine BMP associated proteins having molecular weights of about 14-, 16.5-, 17-, 17.5, 22-, 24-, and 34-dKa.

4. The aggregate of:

(a) hBMP factor having a molecular weight in the range of about 17.5.+-.0.5 kDa, and comprised, as determined by amino acid analysis, of lysine, histidine, arginine, aspartate, threonine, serine, glutamate proline, glycine, alanine, cystine, leucine, tyrosine and phenylalanine; and

(b) at least one BMP-associated protein selected from a group consisting of BMP-associated proteins having molecular weights of about 14-, 22-, 24-, and 34-kDa.

5. The aggregate of:

(a) bBMP factor having a molecular weight in the range of about 18.5.+-.0.5 kDa and and comprised, as determined by amino acid analysis, of lysine, histidine, arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, and phenylalanine; and

(b) at least one BMP associated protein selected from a group consisting of BMP associated proteins having molecular weights of about 14-, 16.5-, 17.0-, 22-, 24-, and 34-kDa.

6. The aggregate of claim 5 consisting essentially of about 7 parts 22-kDa and about 1 part 14-kDa BMP associated proteins, and about 2 parts 18.5.+-.0.5-kDa bBMP factor.

7. The aggregate of hBMP factor and 14-kDa protein of claim 4 wherein said aggregate is insoluble in 0.6 N HCl, soluble in 6M urea, soluble in 4M guanidine HCl; soluble in 0.1% SDS, soluble in 0.02N HCl and partially soluble in ethylene glycol.

8. The aggregate of claim 4, wherein said hBMP factor, as determined by amino acid analysis, is comprised, in approximate mole percentages, of lysine 4%; histidine, 1.5%; arginine, 7%; aspartate, 8%; threonine, 3%; serine, 8%; glutamate 10%; proline, 3.5%; glycine, 25%; alanine, 7%; cystine, 3%; leucine, 7%; tyrosine, 3%; phenylalanine, 2.5%; and about 3 residues/170 residues carboxyglutamic acid.

9. The aggregate of claim 8, said hBMP factor having a molecular weight in the range of about 17.5.+-.0.5 kDa and being trypsin and chymotrypsin labile, alkali sensitive, partially degradable by pepsin and papain, and resistant to chondroitinases A, B and C; amylase; neuroamidase; hyaluronidase; alkaline phosphates; acid phosphatase; chymopapain; collagenase; tyrosinase; thermolysine; RNase and DNase.

10. The aggregate of claim 9, said hBMP factor having a molecular weight of about 17.5.+-.0.5 kDa and being an acidic polypeptide, bindable to hydroxyapetite, having an isoelectric point of 5.0.+-.0.2, being insoluble in chloroform, methanol, absolute alcohol, and acetone and being degraded by acid alcohol solutions.

11. The aggregate of claim 5, wherein said bBMP factor, as determined by amino acid analysis, is comprised, in approximate mole percentages, of lysine, 10%; histidine, 3.5%; arginine, 16.5%; aspartate, 16.5% threonine, 7%, serine, 17.5%; glutamate, 23.5% proline, 9% glycine, 12.5%; alanine, 14.5%; valine, 11%; methionine, 2.5%; isoleucine, 6%; leucine, 15%; tyrosine, 8%; phenylalanine, 7%.

12. The aggregate of claim 5, wherein said 22 kDa protein is comprised, in approximate mole percentages, of lysine, 2.5%; histidine, 2.5%, arginine, 6%; aspartate, 12.5%; threonine, 3.5%; serine, 5.5%; glutamate, 14.5%; proline, 6.5%; glycine, 8.5%; alanine, 6%; cystine, 3.5%; valine, 4.5%; methionine, 2%; isoleucine, 2.5%; leucine, 6.5%; tyrosine, 8.5%; and phenylalanine, 4%.

13. The aggregate of claim 5, wherein said 14-dKa protein is comprised, in approximate mole percentages, of lysine, 4.5%; histidine, 1.5%; arginine, 9%; aspartate, 11.5%; threonine, 2.5%; serine, 6.5%; glutamate, 15%; proline, 5%; glycine, 6% alanine, 8.5%; cystine, 2%; valine, 4%; methionine, 1.5%; isoleucine, 4%; leucine, 7.5%; tyrosine, 6.5%; and phenylalanine, 4%.

Details for Patent 4,761,471

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Discure Medical, Llc CHYMODIACTIN chymopapain INJECTABLE;INJECTION 018663 001 1984-07-09 ⤷  Try it Free The Regents of the University of California (Berkley, CA) 2005-08-02 DISCN search
Discure Medical, Llc CHYMODIACTIN chymopapain INJECTABLE;INJECTION 018663 002 1984-07-09 ⤷  Try it Free The Regents of the University of California (Berkley, CA) 2005-08-02 DISCN search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 001 2004-12-21 ⤷  Try it Free The Regents of the University of California (Berkley, CA) 2005-08-02 RX search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 002 2004-12-21 ⤷  Try it Free The Regents of the University of California (Berkley, CA) 2005-08-02 RX search
Amphastar Pharm AMPHADASE hyaluronidase INJECTABLE;INJECTION 021665 001 2005-11-03 ⤷  Try it Free The Regents of the University of California (Berkley, CA) 2005-08-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Medtronic
Boehringer Ingelheim
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.